Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by Candriam S.C.A.

Candriam S.C.A. decreased its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 26.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 61,192 shares of the company's stock after selling 22,089 shares during the quarter. Candriam S.C.A. owned about 0.20% of Medpace worth $20,330,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the business. R Squared Ltd bought a new position in shares of Medpace in the fourth quarter worth about $30,000. SBI Securities Co. Ltd. bought a new position in shares of Medpace in the fourth quarter worth about $31,000. Stone House Investment Management LLC bought a new position in shares of Medpace in the third quarter worth about $33,000. Ashton Thomas Securities LLC bought a new position in shares of Medpace in the third quarter worth about $37,000. Finally, Jones Financial Companies Lllp grew its holdings in shares of Medpace by 2,750.0% in the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock worth $38,000 after purchasing an additional 110 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company's stock.

Wall Street Analyst Weigh In

Separately, Robert W. Baird upped their price target on shares of Medpace from $354.00 to $362.00 and gave the stock a "neutral" rating in a report on Monday, January 27th. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $381.44.

Remove Ads

Medpace Stock Up 2.2 %

Shares of Medpace stock traded up $7.08 during midday trading on Friday, hitting $332.81. The company had a trading volume of 369,897 shares, compared to its average volume of 302,398. The stock has a market cap of $10.14 billion, a price-to-earnings ratio of 26.35, a PEG ratio of 3.81 and a beta of 1.47. The company has a fifty day simple moving average of $341.10 and a 200 day simple moving average of $342.93. Medpace Holdings, Inc. has a 12-month low of $302.01 and a 12-month high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings data on Monday, February 10th. The company reported $3.67 EPS for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. As a group, analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.